Information Provided By: 
Fly News Breaks for December 21, 2017
RIGL
Dec 21, 2017 | 04:51 EDT
Piper Jaffray analyst Christopher Raymond assumed coverage of Rigel Pharmaceuticals with an Overweight rating and $6 price target. The analyst likes the chances of a favorable FDA decision on fostamitinib in immune thrombocytopenic purpura by the April 17, 2018 action date. He would be a buyer of the stock at current levels.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
